title: Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes.
abstract: BACKGROUND
  Tofacitinib, a novel, oral Janus kinase inhibitor, demonstrated a dose-dependent efficacy for induction of clinical response and remission in patients with active ulcerative colitis (UC). The objective of the current study was to determine the effect of tofacitinib on patient-reported outcomes (PROs).
  
  
  METHODS
  Eligible patients (≥18 years of age) with a diagnosis of active UC (total Mayo score of 6-12 points and moderately-to-severely active disease on sigmoidoscopy) were randomized in a 2:2:2:3:3 ratio to receive oral tofacitinib 0.5 mg, 3 mg, 10 mg, or 15 mg, or placebo twice daily (BID) for 8 weeks. PROs were assessed by the Inflammatory Bowel Disease Questionnaire (IBDQ) and the Inflammatory Bowel Disease Patient-Reported Treatment Impact (IBD PRTI) survey.
  
  
  RESULTS
  At Week 8, mean IBDQ total scores had improved relative to baseline across all five treatment groups (baseline range 123.2-134.5; Week 8 range 149.6-175.4). Improvement from baseline was significantly greater (P = 0.001) for tofacitinib 15 mg BID versus placebo. For tofacitinib 15 mg BID, most patients reported satisfaction or extreme satisfaction, definite preference for tofacitinib, and definite willingness to use tofacitinib again on the IBD PRTI at week 8. Patients achieving endoscopic remission (Mayo endoscopy score of 0) had significantly higher IBDQ scores and favorable PRTI scores than those not achieving endoscopic remission.
  
  
  CONCLUSIONS
  Short-term treatment with tofacitinib BID was associated with dose-dependent improvement in health-related quality of life and patient preferences for tofacitinib. The results complement previously reported efficacy and safety data for the Phase II study. (NCT 00787202, November 6, 2008).
authors: Hospital Clínic de Barcelona. IDIBAPS, CIBERehd, Barcelona, 08036, Spain. JPANES@clinic.ub.es.
authors: Julián
authors: J
authors: Panés
authors: Pfizer Inc, Collegeville, PA, USA. chinyu.su@pfizer.com.
authors: Chinyu
authors: C
authors: Su
authors: Pfizer Inc, Groton, CT, USA. Andrew.G.Bushmakin@pfizer.com.
authors: Andrew G
authors: AG
authors: Bushmakin
authors: Pfizer Inc, Groton, CT, USA. joseph.c.cappelleri@pfizer.com.
authors: Joseph C
authors: JC
authors: Cappelleri
authors: Pfizer Inc, Groton, CT, USA. Carla.M.Mamolo@pfizer.com.
authors: Carla
authors: C
authors: Mamolo
authors: Pfizer Inc, Groton, CT, USA. Paul.J.Healey@pfizer.com.
authors: Paul
authors: P
authors: Healey
mesh_terms: D003093:Colitis, Ulcerative / Q000188:drug therapy*; D003113:Colonoscopy; D006801:Humans; D057240:Patient Preference; D010880:Piperidines / Q000008:administration & dosage / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D011743:Pyrimidines / Q000008:administration & dosage / Q000627:therapeutic use*; D011758:Pyrroles / Q000008:administration & dosage / Q000627:therapeutic use*; D011788:Quality of Life; D012074:Remission Induction; D057566:Self Report; D012720:Severity of Illness Index
chemical_list: D010880:Piperidines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D011758:Pyrroles; C479163:tofacitinib
references: N Engl J Med. 1987 Dec 24;317(26):1625-9
references: 3317057
references: Diabetes Care. 1991 Aug;14(8):738-44
references: 1954811
references: J Clin Gastroenterol. 1992 Jan;14(1):15-9
references: 1556402
references: Gastroenterology. 1994 Feb;106(2):287-96
references: 8299896
references: Inflamm Bowel Dis. 2005 Jan;11(1):24-34
references: 15674110
references: Inflamm Bowel Dis. 2005 Mar;11(3):272-86
references: 15735434
references: Eur J Gastroenterol Hepatol. 2009 May;21(5):558-64
references: 19194304
references: BJU Int. 2010 Sep;106(5):674-80
references: 20184577
references: J Med Chem. 2010 Dec 23;53(24):8468-84
references: 21105711
references: Am J Transplant. 2010 Aug;10(8):1785-95
references: 20626385
references: BJU Int. 2010 Sep;106(5):666-73
references: 20151971
references: J Immunol. 2011 Apr 1;186(7):4234-43
references: 21383241
references: Gastroenterology. 2012 Jan;142(1):46-54.e42; quiz e30
references: 22001864
references: Am J Gastroenterol. 2012 Aug;107(8):1228-35
references: 22613902
references: N Engl J Med. 2012 Aug 16;367(7):616-24
references: 22894574
references: J Eur Acad Dermatol Venereol. 2014 Feb;28(2):192-203
references: 23294276